TMBC Monthly Newsletter, August 2018, V19
|
|
Every month The Microbiome Coalition (TMBC) will bring you the latest in research, news and information to keep you up to date on the microbiome industry.
We welcome your feedback and suggestions for content.
Follow us on Twitter, @TMBCoalition
|
|
Exciting New TMBC Updates!
|
|
5th Annual Arrowhead Translational Microbiome Conference - Planning Underway
The official conference of The Microbiome Coalition (TMBC), the Arrowhead Translational Microbiome Conference, was the first microbiome conference to focus exclusively on the hurdles and challenges to commercial success in the space.
Expanding on this core focus year on year, we continue to offer informative, hands-on workshops, panels sponsored and directed by industry to focus on your concerns and tightly curated content that goes beyond infomercials to provide tangible and useful insights to how your peers are addressing their commercial approach to the space.
Entering it's 5th year into 2019, we are responding to requests by attendees to include more basic research, ensure more work beyond the gut is incorporated into the agenda and expanding our parallel tracks on nutrition and consumer products.
If you are interested in participating - as a speaker, as a panel sponsor, as a track sponsor - please get in touch. Planning is officially underway!
Tentative dates: April 16-18, 2019, Boston MA
TMBC Regional Networking Events
San Francisco, October
Boston, TBD
Stay tuned for further information about exact dates and locations, our first event to be held in San Francisco, with an anticipated October date and a discussion of the infant microbiome.
If you are interested in sponsoring an event in one of these cities, or your city if is not listed and you'd like us to visit, please get in touch at
info@themicrobiomecoalition.com
|
|
FDA Workshop: Science and Regulation of Live Microbiome-Based Products Used to Prevent, Treat, or Cure Diseases in Humans.
The purpose of the public workshop is to exchange information with the scientific community about the clinical, manufacturing, and regulatory considerations associated with live microbiome-based products, when administered to prevent, treat, or cure a disease or condition in humans. The public workshop will bring together government agencies, academia, industry, and other stakeholders involved in research, development, and regulation of live microbiome-based products for such uses. Learn more
here
Azitra Awarded NIH SBIR Grant to Develop Microbiome-based Therapeutic for Netherton Syndrome.
The company has been awarded a $225,000 Small Business Innovation Research (SBIR) Phase I award (R43AR073562) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH). The grant will support development of Azitra’s skin microbiome therapeutic, AZT-02, a Live Biotherapeutic Product (LBP) for treatment of Netherton Syndrome (NS), a severely disabling orphan skin disease.
Full press release
here
Kaleido Biosciences Announces Appointment of Alison Lawton as CEO.
Kaleido Biosciences
today announced that Alison Lawton, Kaleido’s president and chief operating officer (COO), has been appointed to succeed Michael Bonney as chief executive officer.
|
|
Respiratory Issues in Elderly May Relate to Ingestion of Dysbiotic Microbiota.
The elderly have a substantially increased risk of death from pneumonia.
Fewer teeth, poorer dental hygiene, and more dental caries are closely related to dysbiotic shift in the tongue microbiota composition, which might be harmful to the respiratory health of elderly adults with swallowing problems,
new research led by
Yoshihisa Yamashita, PhD, DDS, Section of Preventive and Public Health Dentistry, Division of Oral Health, Growth, and Development, Faculty of Dental Science, Kyushu University.
Full article
here
Changes In The Gut Microbiota Composition During Pregnancy In Patients With Gestational Diabetes Mellitus.
Gestational diabetes mellitus is associated with a moderately increased risk of maternal and perinatal outcomes and lifestyle interventions were reported to provide benefits to the health of GDM women and their babies. It has been hypothesized that at least some of these beneficial effects might be due to the modulation of the maternal microbiota during pregnancy. Research findings suggest that the development of strategies to modulate the gut microbiota might be a potentially useful tool to impact on maternal metabolic health.
Full article
here
Development Of A Gut Microbe–Targeted Nonlethal Therapeutic To Inhibit Thrombosis Potential.
Recent research from the Cleveland Clinic indicates that mechanism-based inhibition of
gut microbial TMA and TMAO production reduces thrombosis potential, a critical adverse complication in heart disease. It also offers a generalizable approach for the selective nonlethal targeting of gut microbial enzymes linked to host disease limiting systemic exposure of the inhibitor in the host.
Learn more
here
Mass Antibiotic Dosing Alters Children's Gut Microbiome, Improves Mortality.
Additional analysis of the MORDOR study
found a significant 18% reduction in childhood mortality with mass azithromycin administrations in Niger. The mechanism of mortality reduction is not clear, although the functional state of the gut microbiome has been linked in numerous ways to a child’s health and disease. Read more
here
|
|
Forget Milk, Crickets Do A Body Good!
More than 2 billion people around the world regularly consume insects as part of their diet and while much has been made about the environmental benefits of doing so, here's one more reason to consider eating insects. A small clinical study demonstrated that eating insects reduced markers of inflammation and increased beneficial bacteria in the gut. So before you say gross, consider your health.
Full article
here
Science Writing Prize 2018 – The Human Microbiome and Cancer: Friend or Foe?
In the first of four blog posts by the winner and runners-up of the Mel Greaves Science Writing Prize 2018, Dr Samantha Nimalasena, runner-up, writes about how our own microbiomes and immune systems can be used to tackle cancer. Read more
here
|
|
Scientist, Microbiology, GALT
GALT is currently seeking a Microbiologist to i) help develop novel technologies, methods and applications for high-throughput microbial cultivation and screening, and ii) support GALT collaboration and early customer development efforts.
Learn more
here
Molecular Biologist II, Quorum Innovations
Quorum Innovations is seeking a molecular biologist to help maintain a state-of-the-art research and development program to include computational biology, genomics, proteomics and compound purification methods targeting Company disease initiatives; Implementing and undertaking testing strategies which investigate, identify and validate novel biomarkers and potential mechanisms of action in human organotypic disease models; Conducting bio-extract testing with optimization/purification for biological activity. Learn more
here
Director, Microbiome Research, J&J
As Director of Microbiome Research, reporting into the Global Head of the Janssen Human Microbiome Institute, you will give guidance and mentorship to members of the team, and make your microbiome expertise available across the organization. As Director you will be the primary responsible for driving several of our research projects towards and through product development stage, and for identifying additional internal and external beneficial partnerships. Learn more
here
|
|
Grants, Competitions, Prizes, Opportunities
Mosaic Standards Challenge to Advance Microbiome Science.
Supported by Janssen Research & Development, LLC, the Standards Challenge aims to capture the diversity of protocols for NGS-based microbiome profiling methods and analyses as a first step in understanding their impact on the variability of the taxonomic results. Learn more
here
Participate in a Research Study: Microbiome Individuality and Stability Over Time.
A research study at Stanford University is seeking to better understand h
ow diet affects the
composition of the microbial species living in the large intestine and what effect an identical diet has on different individuals. Additional information and qualifications
here
|
|
JOIN TMBC
Members of TMBC participate on our committees, attend our events, generate networking and business development opportunities and, most importantly, contribute to the growth and success of a unique organization that is positioned to ensure that public opinion and policy pave the way for microbiome based therapeutics, diagnostics and direct-to-consumer services and products.
Membership Categories
• Sole proprietor (legal, consulting, other) • Academic and clinical institutions
• Patient advocacy groups • Industry/trade associations
• Corporations (pharmaceutical, diagnostic,bioinformatics, other)
Benefits of Membership
• Shape the Future of Microbiome Policy • Curated research library
• Monthly newsletter • White papers • Extended network • Job listings • Event listings
See our
flyer
for more details
|
|
Promoting Greater Understanding of the Role
of the Microbiome in Human Health and Wellness
|
|
|
|
|
|
|
